Safety and efficacy for the treatment of C1-C2 patients with a new method Hemodynamic Hybrid Nd YAG 1064 LASER and Cryo-Sclerotherapy (HHLCS).

Objective: To evaluate the safety and efficacy of Hemodynamic Hybrid LASER Cryo-Sclerotherapy (HHLCS) for the treatment of CVD in patients with telangiectasias, reticular veins, and varicose veins.

Methods: This retrospective cohort included patients classified as C1 and C2 "low" treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler Ultrasound Venous Mapping (DUVM) for evidence of deep and superficial reflux and standardized pre- and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67-75% Dextrose injection.

Results: A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50-69%), or complete (70-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% (34/41) of patients. Post-inflammatory hyperpigmentation (PIH) was the most frequent complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.

Conclusions: HHLCS appears to be a safe and effective office-based treatment for C1 and C2 "low" patients, potentially reducing the need for invasive saphenous vein procedures in early-stage CVD.